{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Angiotensin converting enzyme (ACE) inhibitors", "Dynamics", "Hypertension", "In-silico", "Medicinal plants", "Molecular docking", "Simulation"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36245815", "DateRevised": {"Year": "2023", "Month": "10", "Day": "14"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "10", "Day": "13"}], "Language": ["eng"], "ELocationID": ["20", "10.1007/s40203-022-00135-z"], "Journal": {"ISSN": "2193-9616", "JournalIssue": {"Volume": "10", "Issue": "1", "PubDate": {"Year": "2022"}}, "Title": "In silico pharmacology", "ISOAbbreviation": "In Silico Pharmacol"}, "ArticleTitle": "Angiotensin converting enzyme inhibitors from medicinal plants: a molecular docking and dynamic simulation approach.", "Pagination": {"StartPage": "20", "MedlinePgn": "20"}, "Abstract": {"AbstractText": ["Angiotensin converting enzyme (ACE) is a key enzyme and mediator in the aetiology of high blood pressure (HBP) and hypertension. As one of the leading cause of untimely death worldwide, there is a lot of research and studies on the management and treatment of hypertension. The usage of medicinal plants in the management of hypertension as alternative to synthetic allopathic drugs is a common practice in folkloric and traditional medicine. Therefore, this study was aimed to investigate the ACE inhibitory activity of some medicinal plants which are commonly used in the treatment of HBP in southwestern part of Nigeria using extensive in-silico approach. Compounds identified in the plants through GC-MS technique, together with Lisinopril were docked against ACE protein. It was observed that only 40 of the compounds had binding affinity\u2009\u2265\u2009- 6.8\u00a0kcal/mol which was demonstrated by the standard drug (lisinopril). Interaction between the compounds and ACE was via conventional hydrogen, carbon hydrogen, alkyl, pi-alkyl, pi-carbon, and Van Der Wall bonds among others. Most of these compounds exhibited drug like properties, without violating majority of the physicochemical descriptors and Lipinski rule of 5. The ADMET evaluation revealed that only 2 compounds (cyclopentadecanone and oxacycloheptadecan-2-one) which were identified in <i>Bacopa florinbunda</i> plant were predicted non-toxic and thus were subjected to molecular dynamics and simulation with ACE. From the molecular dynamics and mechanics analysis, both cyclopentadecanone and oxacycloheptadecan-2-one showed high stability and inhibitory potentials when bound to ACE. Oxacycloheptadecan-2-one was more stable than lisinopril and cyclopentadecanone in the ligand-ACE complex; we therefore suggested its experimental and clinical validation as drug candidates for the treatment of hypertension.", "The online version contains supplementary material available at 10.1007/s40203-022-00135-z."], "CopyrightInformation": "\u00a9 The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law."}, "AuthorList": [{"Identifier": ["0000-0002-8185-5662"], "AffiliationInfo": [{"Identifier": ["grid.411270.1", "0000 0000 9777 3851"], "Affiliation": "Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo Nigeria."}], "LastName": "Fadahunsi", "ForeName": "Olumide Samuel", "Initials": "OS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.411270.1", "0000 0000 9777 3851"], "Affiliation": "Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo Nigeria."}], "LastName": "Olorunnisola", "ForeName": "Olubukola Sinbad", "Initials": "OS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.411270.1", "0000 0000 9777 3851"], "Affiliation": "Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo Nigeria."}, {"Identifier": ["grid.16463.36", "0000 0001 0723 4123"], "Affiliation": "Molecular Bio-Computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, 4001 South Africa."}], "LastName": "Adegbola", "ForeName": "Peter Ifeoluwa", "Initials": "PI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.16463.36", "0000 0001 0723 4123"], "Affiliation": "Molecular Bio-Computation and Drug Design Laboratory, School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban, 4001 South Africa."}], "LastName": "Subair", "ForeName": "Temitayo I", "Initials": "TI"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": ["grid.411270.1", "0000 0000 9777 3851"], "Affiliation": "Department of Biochemistry, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomoso, Oyo Nigeria."}], "LastName": "Elegbeleye", "ForeName": "Oluwabamise Emmanuel", "Initials": "OE"}], "GrantList": [{"GrantID": "PG/15/30/31390", "Acronym": "BHF_", "Agency": "British Heart Foundation", "Country": "United Kingdom"}, {"GrantID": "TRP 206", "Acronym": "FWF_", "Agency": "Austrian Science Fund FWF", "Country": "Austria"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Germany", "MedlineTA": "In Silico Pharmacol", "NlmUniqueID": "101623954", "ISSNLinking": "2193-9616"}, "CoiStatement": "Conflict of interestOn behalf of all authors, the corresponding author states that there is no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ahmad I, Azminah A, Mulia K, Yanuar A, Mun'im A. Angiotensin-converting enzyme inhibitory activity of polyphenolic compounds from Peperomia pellucida (L.) Kunth: an in silico molecular docking study. J Appl Pharm Sci. 2019;9(08):25\u2013031."}, {"Citation": "Alavijeh MS, Chishty M, Qaiser Z, Palmer AM. Drug metabolism and pharmacokinetics, the blood\u2013brain barrier, and central nervous system drug discovery. J Am Soc Exp Neurother. 2005;2:554\u2013557.", "ArticleIdList": ["PMC1201315", "16489365"]}, {"Citation": "Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5:744\u2013749. doi: 10.1016/j.jaip.2017.02.018.", "ArticleIdList": ["10.1016/j.jaip.2017.02.018", "PMC5476207", "28377081"]}, {"Citation": "Berendsen HJC, Postma JPM, Van Gunsteren WF, Dinola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81:3684\u20133690. doi: 10.1063/1.448118.", "ArticleIdList": ["10.1063/1.448118"]}, {"Citation": "Bohnert T, Prakash C. ADME profiling in drug discovery and development: an overview. Encycl Drug Metab Interact. 2012 doi: 10.1002/9780470921920.edm021.", "ArticleIdList": ["10.1002/9780470921920.edm021"]}, {"Citation": "Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, Jr, Onufriev A, Simmerling C, Wang B, Woods RJ. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668\u20131688. doi: 10.1002/jcc.20290.", "ArticleIdList": ["10.1002/jcc.20290", "PMC1989667", "16200636"]}, {"Citation": "Case DA, Ben-Shalom IY, Brozell SR, Cerutti DS, Cheatham TE, III, Cruzeiro VWD, Darden TA, Duke RE, Ghoreishi D, Gilson MK, Gohlke H, Goetz AW, Greene D, Harris R, Homeyer N, Huang Y, Izadi S, Kovalenko A, Kurtzman T, Lee TS, LeGrand S, Li P, Lin C, Liu J, Luchko T, Luo R, Mermelstein DJ, Merz KM, Miao Y, Monard G, Nguyen C, Nguyen H, Omelyan I, Onufriev A, Pan F, Qi R, Roe DR, Roitberg A, Sagui C, Schott-Verdugo S, Shen J, Simmerling CL, Smith J, Salomon-Ferrer R, Swails J, Walker RC, Wang J, Wei H, Wolf RM, Wu X, Xiao L, York DM, Kollman PA. Amber. San Francisco: University of California; 2018."}, {"Citation": "Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson B. The oxidative stress mediator 4-hydroxynonenal anintracellularagonistofthenuclearreceptorperoxisomeproliferator-activated receptor beta/delta(PPARbeta/delta) Free Radic Biol Med. 2007;42:1155\u20131164. doi: 10.1016/j.freeradbiomed.2007.01.003.", "ArticleIdList": ["10.1016/j.freeradbiomed.2007.01.003", "PMC1892209", "17382197"]}, {"Citation": "Correia MA, Hollenberg PF. Inhibition of cytochrome P450 enzymes. In: de Montellano PRO, editor. Cytochrome P450. Cham: Springer International Publishing; 2015. pp. 177\u2013259."}, {"Citation": "Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:115e666. doi: 10.1101/gr.184901.", "ArticleIdList": ["10.1101/gr.184901", "11435397"]}, {"Citation": "Deng Z, Liu Y, Wang J, Wu S, Geng L, Sui Z. Antihypertensive effects of two novel angiotensin IConverting Enzyme (ACE) inhibitory peptides from gracilariopsis lemaneiformis (Rhodophyta) in spontaneously hypertensive rats (SHRs) Mar Drugs. 2018;16(9):299\u2013305. doi: 10.3390/md16090299.", "ArticleIdList": ["10.3390/md16090299", "PMC6163600", "30150552"]}, {"Citation": "Di L, Artursson P, Benet LZ, Houston JB, Kansy M, Kerns EH, Lennern\u00e4s H, Smith DA, Sugano K. The critical role of passive permeability in designing successful drugs. Chem Med Chem. 2020;15:1862\u20131874. doi: 10.1002/cmdc.202000419.", "ArticleIdList": ["10.1002/cmdc.202000419", "32743945"]}, {"Citation": "Esteves F, Rueff J, Kranendonk M. The central role of cytochrome P450 in xenobiotic metabolism. A brief review on a fascinating enzyme family. J Xenobiot. 2021;11:94\u2013114. doi: 10.3390/jox11030007.", "ArticleIdList": ["10.3390/jox11030007", "PMC8293344", "34206277"]}, {"Citation": "Garrido A, Lepailleur A, Mignani SM, Dallemagne P, Rochais C. hERG toxicity assessment: useful guidelines for drug design. Eur J Med Chem. 2020;195:112290. doi: 10.1016/j.ejmech.2020.112290.", "ArticleIdList": ["10.1016/j.ejmech.2020.112290", "32283295"]}, {"Citation": "Gentry KA, Anantharamaiah GM, Ramamoorthy A. Probing protein\u2013protein and protein\u2013substrate interactions in the dynamic membrane-associated ternary complex of cytochromes P450, b5, and reductase. Chem Commun Camb Engl. 2019;55:13422\u201313425. doi: 10.1039/C9CC05904K.", "ArticleIdList": ["10.1039/C9CC05904K", "PMC6879317", "31638629"]}, {"Citation": "Guengerich FP, Waterman MR, Egli M. Recent structural insights into cytochrome P450 function. Trends Pharmacol Sci. 2016;37:625\u2013640. doi: 10.1016/j.tips.2016.05.006.", "ArticleIdList": ["10.1016/j.tips.2016.05.006", "PMC4961565", "27267697"]}, {"Citation": "Hanser T, Steinmetz FP. Avoiding hERG-liability in drug design via synergetic combinations of different (Q)SAR methodologies and data sources: a case study in an industrial setting. J Cheminform. 2019;11:9. doi: 10.1186/s13321-019-0334-y.", "ArticleIdList": ["10.1186/s13321-019-0334-y", "PMC6689868", "30712151"]}, {"Citation": "Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569\u2013580. doi: 10.1016/S0092-8674(01)00243-4.", "ArticleIdList": ["10.1016/S0092-8674(01)00243-4", "11239413"]}, {"Citation": "Khoutoul M, Djedouani A, Lamsayah M, Abrigach F, Touzani R. Liquid\u2013liquid extraction of metalions, DFT and TD-DFT analysis for some pyrane derivatives with high selectivity for Fe(II) and Pb(II) Sep Sci Technol. 2016;51(7):1112\u20131123. doi: 10.1080/01496395.2015.1107583.", "ArticleIdList": ["10.1080/01496395.2015.1107583"]}, {"Citation": "Kloting N, Bluher M. Adipocyte dysfunction, inflammation and metabolic syndrome. Rev Endocr Metab Disord. 2014;15:277\u2013287. doi: 10.1007/s11154-014-9301-0.", "ArticleIdList": ["10.1007/s11154-014-9301-0", "25344447"]}, {"Citation": "Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, Chong L, Lee M, Lee T, Duan Y, Wang W, Donini O, Cieplak P, Srinivasan J, Case DA, Cheatham III TE. Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res. 2000;33:889\u2013897. doi: 10.1021/ar000033j.", "ArticleIdList": ["10.1021/ar000033j", "11123888"]}, {"Citation": "Lawal M, Olotu FA, Soliman MES. Across the blood-brain barrier: neurotherapeutic screening and characterization of naringenin as a novel CRMP-2 inhibitor in the treatment of Alzheimer\u2019s disease using bioinformatics and computational tools. Comput Biol Med. 2018;98:168\u2013177. doi: 10.1016/j.compbiomed.2018.05.012.", "ArticleIdList": ["10.1016/j.compbiomed.2018.05.012", "29860210"]}, {"Citation": "Lee GR, Shin WH, Park HB, Shin S, Seok C. Conformational sampling of flexible ligand-binding protein loops. Bull Korean Chem Soc. 2012;33(3):770\u2013774. doi: 10.5012/bkcs.2012.33.3.770.", "ArticleIdList": ["10.5012/bkcs.2012.33.3.770"]}, {"Citation": "Leung L, Kalgutkar AS, Obach RS. Metabolic activation in drug induced liver injury. Drug Metab Rev. 2012;44:18\u201333. doi: 10.3109/03602532.2011.605791.", "ArticleIdList": ["10.3109/03602532.2011.605791", "21939431"]}, {"Citation": "Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1\u20133):3\u201326. doi: 10.1016/S0169-409X(00)00129-0.", "ArticleIdList": ["10.1016/S0169-409X(00)00129-0", "11259830"]}, {"Citation": "Liu X, Fernandez M, Wouters MA, Heyberger S, Husain A. Arg-1098 is critical for the chloride dependence of human angiotensin-1 converting enzyme C-domain catalytic activity. J Biol Chem. 2001;276:33518\u201333525. doi: 10.1074/jbc.M101495200.", "ArticleIdList": ["10.1074/jbc.M101495200", "11432860"]}, {"Citation": "Ma FF, Wang H, Wei CK, Thakur K, Wei Z, Jiang L. Three novel ACE inhibitory peptides isolated from Ginkgo biloba seeds: purification, inhibitory kinetic and mechanism. Front Pharmacol. 2018;9:1579. doi: 10.3389/fphar.2018.01579.", "ArticleIdList": ["10.3389/fphar.2018.01579", "PMC6340938", "30697161"]}, {"Citation": "MacLeod-Carey D, Solis-C\u00e9spedes E, Lamazares E, Mena-Ulecia K. Evaluation of new antihypertensive drugs designed in silico using Thermolysin as a target. Saudi Pharm J. 2020;28:582\u2013592. doi: 10.1016/j.jsps.2020.03.010.", "ArticleIdList": ["10.1016/j.jsps.2020.03.010", "PMC7229335", "32435139"]}, {"Citation": "Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018;19(1):38\u201354. doi: 10.2174/1389450118666170125144557.", "ArticleIdList": ["10.2174/1389450118666170125144557", "28124606"]}, {"Citation": "Messerli FH, Bangalore S, Bavishi C, Rimoldi SF. Angiotensin-converting enzyme inhibitors in hypertension to use or not to use? J Am Coll Cardiol. 2018;71(13):1474\u20131482. doi: 10.1016/j.jacc.2018.01.058.", "ArticleIdList": ["10.1016/j.jacc.2018.01.058", "29598869"]}, {"Citation": "Mills KT, Bundy JD, Kelly TN, Reed JE, Kearny PM, Reynolds K, Chen J, He J. Global disparities of hypertension prevalence and control. Circulation. 2016;134:441\u2013450. doi: 10.1161/CIRCULATIONAHA.115.018912.", "ArticleIdList": ["10.1161/CIRCULATIONAHA.115.018912", "PMC4979614", "27502908"]}, {"Citation": "M\u00f6llsten A, Stegmayr B, Wiklund PG. Genetic polymorphisms in the renin-angiotensin system confer increased risk of stroke independently of blood pressure: a nested case\u2013control study. J Hypertens. 2008;26:1367\u20131372. doi: 10.1097/HJH.0b013e3282fe1d55.", "ArticleIdList": ["10.1097/HJH.0b013e3282fe1d55", "18551012"]}, {"Citation": "Myatt GJ, Ahlberg E, Akahori Y, Allen D, Amberg A, Anger LT, Aptula A, Auerbach S, Beilke L, Bellion P, Benigni R, Bercu J, Booth ED, Bower D, Brigo A, Burden N, Cammerer Z, Cronin MTD, Cross KP, Custer L, Dettwiler M, Dobo K, Ford KA, Fortin MC, Gad-McDonald SE, Gellatly N, Gervais V\u00e9, Glover KP, Glowienke S, Van Gompel J, Gutsell S, Hardy B, Harvey JS, Hillegass J, Honma M, Hsieh J-H, Hsu C-W, Hughes K, Johnson C, Jolly R, Jones D, Kemper R, Kenyon MO, Kim MT, Kruhlak NL, Kulkarni SA, K\u00fcmmerer K, Leavitt P, Majer B, Masten S, Miller S, Moser J, Mumtaz M, Muster W, Neilson L, Oprea TI, Patlewicz G, Paulino A, Lo Piparo E, Powley M, Quigley DP, Reddy MV, Richarz A-N, Ruiz P, Schilter B, Serafimova R, Simpson W, Stavitskaya L, Stidl R, Suarez-Rodriguez D, Szabo DT, Teasdale A, Trejo-Martin A, Valentin J-P, Vuorinen A, Wall BA, Watts P, White AT, Wichard J, Witt KL, Woolley A, Woolley D, Zwickl C, Hasselgren C. In silico toxicology protocols. Regul Toxicol Pharmacol. 2018 doi: 10.1016/j.yrtph.2018.04.014.", "ArticleIdList": ["10.1016/j.yrtph.2018.04.014", "PMC6026539", "29678766"]}, {"Citation": "Natesh R, Schwager SLU, Sturrock ED, Acharya KR. Crystal structure of the human angiotensin-converting enzyme\u2013lisinopril complex. Nature. 2003;421:551\u2013554. doi: 10.1038/nature01370.", "ArticleIdList": ["10.1038/nature01370", "12540854"]}, {"Citation": "Norris W, Paredes AH, Lewis JH. Drug-induced liver injury in 2007. Curr Opin Gastroenterol. 2008;24(3):287\u2013297. doi: 10.1097/MOG.0b013e3282f9764b.", "ArticleIdList": ["10.1097/MOG.0b013e3282f9764b", "18408456"]}, {"Citation": "Obode OC, Adebayo AH, Omonhinmin CA, Yakubu OF. A systematic review of medicinal plants used in Nigeria for hypertension management. Int J Pharm Res. 2020;12(4):2231\u20132275."}, {"Citation": "O'Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB, Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ, Zhao DX. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):e78\u2013e140. doi: 10.1016/j.jacc.2012.11.019.", "ArticleIdList": ["10.1016/j.jacc.2012.11.019", "23256914"]}, {"Citation": "Olotu FA, Soliman MES. From mutational inactivation to aberrant gain-of-function: unraveling the structural basis of mutant p53 oncogenic transition. J Cell Biochem. 2018;119:2646\u20132652. doi: 10.1002/jcb.26430.", "ArticleIdList": ["10.1002/jcb.26430", "29058783"]}, {"Citation": "Pan D, Cao J, Guo H, Zhao B. Studies on purification and the molecular mechanism of a novel ACE inhibitory peptide from whey protein hydrolysate. Food Chem. 2012;130(1):121\u2013126. doi: 10.1016/j.foodchem.2011.07.011.", "ArticleIdList": ["10.1016/j.foodchem.2011.07.011"]}, {"Citation": "Pandit A, Sachdeva T, Bafna P. Drug-induced hepatotoxicity: a review. J Appl Pharm Sci. 2012;02:233\u2013243."}, {"Citation": "Parasuraman S. Toxicological screening. J Pharmacol Pharmacother. 2011;2(2):74\u201379. doi: 10.4103/0976-500X.81895.", "ArticleIdList": ["10.4103/0976-500X.81895", "PMC3127354", "21772764"]}, {"Citation": "Priest BT, Bell IM, Garcia ML. Role of hERG potassium channel assays in drug development. Landes Biosci. 2008;2(2):87\u201393.", "ArticleIdList": ["18849661"]}, {"Citation": "Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol. 2012;302(6):H1219\u2013H1230. doi: 10.1152/ajpheart.00796.2011.", "ArticleIdList": ["10.1152/ajpheart.00796.2011", "PMC3311482", "22227126"]}, {"Citation": "Qi C, Zhang R, Liu F, Zheng T, Wu W. Molecular mechanism of interactions between inhibitory tripeptide GEF and angiotensin-converting enzyme in aqueous solutions by molecular dynamic simulations. J Mol Liq. 2018;249:389\u2013396. doi: 10.1016/j.molliq.2017.11.033.", "ArticleIdList": ["10.1016/j.molliq.2017.11.033"]}, {"Citation": "Raji V, Loganathan C, Sadhasivam G, Kandasamy S, Poomani K, Thayumanavan P. Purification of fucoxanthin from Sargassum wightii Greville and understanding the inhibition of angiotensin 1-converting enzyme: an in vitro and in silico studies. Int J Biol Macromol. 2020;148(2020):696\u2013703. doi: 10.1016/j.ijbiomac.2020.01.140.", "ArticleIdList": ["10.1016/j.ijbiomac.2020.01.140", "31954795"]}, {"Citation": "Rakib A, Nain Z, Sami SA, Mahmud S, Islam A, Ahmed S, Siddiqui ABF, Babu SMOF, Hossain P, Shahriar A, Nainu F, Emran TB, Simal-Gandara J. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARSCoV-2: an in silico investigation. Brief Bioinform. 2021;22:1476\u20131498. doi: 10.1093/bib/bbab045.", "ArticleIdList": ["10.1093/bib/bbab045", "PMC7929402", "33623995"]}, {"Citation": "Ray AK, Gupta PSS, Panda SK, Biswal S, Bhattacharya U, Rana MK. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: molecular insights into improved therapeutic discovery. Comput Biol Med. 2022;142:105183. doi: 10.1016/j.compbiomed.2021.105183.", "ArticleIdList": ["10.1016/j.compbiomed.2021.105183", "PMC8714248", "34986429"]}, {"Citation": "Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 1977;23:327\u2013341. doi: 10.1016/0021-9991(77)90098-5.", "ArticleIdList": ["10.1016/0021-9991(77)90098-5"]}, {"Citation": "Sembuling K, Sembuling P. Essential of medical physiology. 6. Delhi: New Jaypee Brothers Medical Publishers; 2012."}, {"Citation": "Singh D, Cho WC, Upadhyay G. Drug-induced liver toxicity and prevention by herbal antioxidants: an overview. Front Physiol. 2016;6(363):1\u201317. doi: 10.3389/fphys.2015.00363.", "ArticleIdList": ["10.3389/fphys.2015.00363", "PMC4726750", "26858648"]}, {"Citation": "Sorlie PD, Allison MA, Aviles-Santa ML, Cai J, Daviglus ML, Howard AG, Kaplan R, LaVange LM, Raij L, Schneiderman N, Wassertheil- SS, Talavera GA. Prevalence of hypertension, awareness, treatment, and control in the Hispanic community health study/study of Latinos. Am J Hypertens. 2014;27:793\u2013800. doi: 10.1093/ajh/hpu003.", "ArticleIdList": ["10.1093/ajh/hpu003", "PMC4017932", "24627442"]}, {"Citation": "Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin\u2013angiotensin system in kidney physiology. Compr Physiol. 2014;4(3):1201\u20131228. doi: 10.1002/cphy.c130040.", "ArticleIdList": ["10.1002/cphy.c130040", "PMC4137912", "24944035"]}, {"Citation": "Su M, Zhang Q, Bai X. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet. 2017;390:2559\u20132568. doi: 10.1016/S0140-6736(17)32476-5.", "ArticleIdList": ["10.1016/S0140-6736(17)32476-5", "29102087"]}, {"Citation": "Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun P. Targeting P-glycoprotein and SORCIN: dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca2\u00fe-mediated apoptosis pathways in MCF-7/ADR and K562/ADR. J Cell Physiol. 2018;233:3066e79. doi: 10.1002/jcp.26087.", "ArticleIdList": ["10.1002/jcp.26087", "28681913"]}, {"Citation": "Tabassum N, Ahmad F. Role of natural herbs in the treatment of hypertension. Pharmacogn Rev. 2011;5(9):30\u201340. doi: 10.4103/0973-7847.79097.", "ArticleIdList": ["10.4103/0973-7847.79097", "PMC3210006", "22096316"]}, {"Citation": "Tahir RA, Bashir A, Yousaf MN, Ahmed A, Dali Y, Khan S. In silico identification of angiotensin-converting enzyme inhibitory peptides from MRJP1. PLoS\u00a0One. 2020;15(2):e0228265. doi: 10.1371/journal.pone.0228265.", "ArticleIdList": ["10.1371/journal.pone.0228265", "PMC6996805", "32012183"]}, {"Citation": "Toyoda Y, Miyashita T, Endo S, Tsuneyama K, Fukami T, Nakajima M. Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol Lett. 2011;204:17\u201324. doi: 10.1016/j.toxlet.2011.03.031.", "ArticleIdList": ["10.1016/j.toxlet.2011.03.031", "21501669"]}, {"Citation": "Tseng DS, Kwong J, Rezvani F, Coates AO. Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med. 2010;123:183.e11-5. doi: 10.1016/j.amjmed.2009.06.032.", "ArticleIdList": ["10.1016/j.amjmed.2009.06.032", "20103031"]}, {"Citation": "Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;6(45):2615\u20132623. doi: 10.1021/jm020017n.", "ArticleIdList": ["10.1021/jm020017n", "12036371"]}, {"Citation": "Vijay U, Gupta S, Mathur P, Suravajhala P, Bhatnagar P. Microbial mutagenicity assay. Ames Test Bio Protocol. 2018;8(6):1\u201315.", "ArticleIdList": ["PMC8203972", "34179285"]}, {"Citation": "Villanueva-Paz M, Mor\u00e1n L, L\u00f3pez-Alc\u00e1ntara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice. Antioxidants. 2021;10(3):390. doi: 10.3390/antiox10030390.", "ArticleIdList": ["10.3390/antiox10030390", "PMC8000729", "33807700"]}, {"Citation": "Wadood A, Ahmed N, Shah L, Ahmad A, Hassan H, Shams S. In-silico drug design. An approach which revolutionarised the drug discovery process. OA Drug Des Deliv. 2013;1(1):3\u20137."}, {"Citation": "Wang J. Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des. 2009;15(19):2195\u20132219. doi: 10.2174/138161209788682514.", "ArticleIdList": ["10.2174/138161209788682514", "19601823"]}, {"Citation": "Wang B, Kang IS, Lee JY. Ensemble simulations of Asian-Australian monsoon variability by 11 AGCMs. J Clim. 2004;17:803\u2013818. doi: 10.1175/1520-0442(2004)017<0803:ESOAMV>2.0.CO;2.", "ArticleIdList": ["10.1175/1520-0442(2004)017<0803:ESOAMV>2.0.CO;2"]}, {"Citation": "Wang W, McKinnie SM, Farhan M, Paul M, McDonald T, McLean B, Llorens-Cortes C, Hazra S, Murray AG, Vederas JC, Oudit GY. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system. Hypertension. 2016;68(2):365\u2013377. doi: 10.1161/HYPERTENSIONAHA.115.06892.", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.115.06892", "27217402"]}, {"Citation": "Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 2011;89:788\u2013790. doi: 10.1038/clpt.2011.63.", "ArticleIdList": ["10.1038/clpt.2011.63", "21593756"]}, {"Citation": "Wong M. Angiotensin converting enzymes. Handb Horm. 2016 doi: 10.1016/B978-0-12-801028-0.00254-3.", "ArticleIdList": ["10.1016/B978-0-12-801028-0.00254-3"]}, {"Citation": "Yan W, Lin G, Zhang R, Liang Z, Wu WW. Studies on molecular mechanism between ACE and inhibitory peptides in different bioactivities by 3D-QSAR and MD simulations. J Mol Liq. 2020;304:112702. doi: 10.1016/j.molliq.2020.112702.", "ArticleIdList": ["10.1016/j.molliq.2020.112702"]}, {"Citation": "Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103\u2013141. doi: 10.1016/j.pharmthera.2012.12.007.", "ArticleIdList": ["10.1016/j.pharmthera.2012.12.007", "23333322"]}, {"Citation": "Zhou M, Du K, Ji PJ, Feng W. Molecular mechanism of the interactions between inhibitory tripeptides and angiotensin-converting enzyme. Biophys Chem. 2012;168\u2013169:60\u201366. doi: 10.1016/j.bpc.2012.05.002.", "ArticleIdList": ["10.1016/j.bpc.2012.05.002", "22835627"]}, {"Citation": "Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, Singleton RK. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957\u2013980. doi: 10.1016/s0140-6736(21)01330-1.", "ArticleIdList": ["10.1016/s0140-6736(21)01330-1", "PMC8446938", "34450083"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "7", "Day": "26"}, {"Year": "2022", "Month": "9", "Day": "20"}, {"Year": "2022", "Month": "10", "Day": "17", "Hour": "4", "Minute": "20"}, {"Year": "2022", "Month": "10", "Day": "18", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "18", "Hour": "6", "Minute": "1"}, {"Year": "2023", "Month": "10", "Day": "13"}], "PublicationStatus": "epublish", "ArticleIdList": ["36245815", "PMC9561457", "10.1007/s40203-022-00135-z", "135"]}}], "PubmedBookArticle": []}